NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

Core Insights - Elanco Animal Health has appointed Dr. Stacey Ma to its Board of Directors, effective immediately, enhancing the company's expertise in biopharmaceutical development and manufacturing [1][2]. Company Overview - Elanco Animal Health is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat diseases in farm animals and pets, with nearly 70 years of heritage in the industry [6]. Leadership and Expertise - Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, currently serving as Executive Vice President at Gilead Sciences, where she oversees product and portfolio strategy, technical development, supply chain, quality, CMC regulatory, and manufacturing operations [3][5]. - Dr. Ma has held leadership positions at Sana Biotechnology and Genentech/Roche, contributing significantly to product development and technical innovation [3][4]. Strategic Contributions - Dr. Ma's expertise in Chemistry, Manufacturing and Controls (CMC) strategy and technical operations is expected to be valuable as Elanco transitions significant products from research to manufacturing scale-up [5]. - Her role will also support Elanco's Innovation, Portfolio and Productivity (IPP) strategy, aimed at developing a consistent flow of high-impact innovations in the company's next-generation pipeline [5].

NEW YORK, Nov. 10, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- A federal lawsuit has been filed in the U.S. District Court of Maryland against Elanco Animal Health Inc. and specific executives, accusing them of making false and misleading statements between November 7, 2023, and June 26, 2024. Hagens Berman urges Elanco Animal Health Incorporated (NYSE: ELAN) investors who suffered substantial losses to submit your losses now. Class Period: Nov. 7, 2023 – June 26, 2024Lead Plaintiff Deadline: Dec. 6, 2024 Visit: www.hbss ...

2024 Earnings – Third Quarter November 7, 2024 2024 | Q3 Earnings 2 Notices and Disclaimers Forward-Looking Statements. This press release contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning product launches and revenue from such products, our 2024 full year and fourth quarter guidance, 2025 outlook and long-term expectations, our expectations regarding debt levels, and expectations regarding our industry and our operati ...

Elanco Animal Health Incorporated (NYSE:ELAN) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Katy Grissom - Head, Investor Relations Jeff Simmons - President & CEO Todd Young - EVP & CFO Conference Call Participants Michael Ryskin - Bank of America Merrill Lynch Jonathan Block - Stifel Erin Wright - Morgan Stanley Brandon Vazquez - William Blair Balaji Prasad - Barclays Chris Schott - JPMorgan Mike DiFiore - Evercore ISI David Westenberg - Piper Sandler Navann Ty - BNP Par ...

For the quarter ended September 2024, Elanco Animal Health Incorporated (ELAN) reported revenue of $1.03 billion, down 3.6% over the same period last year. EPS came in at $0.13, compared to $0.18 in the year-ago quarter.The reported revenue represents a surprise of -0.37% over the Zacks Consensus Estimate of $1.03 billion. With the consensus EPS estimate being $0.12, the EPS surprise was +8.33%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expec ...

PHILADELPHIA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Elanco Animal Health Inc. (“Elanco” or the “Company”) (NYSE: ELAN). The lawsuit has been filed on behalf of purchasers of ELANCO securities between November 7, 2023 and June 26, 2024, inclusive (the “Class Period”). CLICK HERE TO LEARN MORE ABOUT THIS LAWSUIT. Investors who purchased or acquired ELANCO securities during the Class Period may, no later than DECEMBER 6, 2024, seek to be appointed as a lead ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, no par value ELAN New York Stock Exchange Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ...